Payment overview · 2025
General Payments
2 reported records · 2 companies
Healthcare provider profile · identity verified
Allopathic & Osteopathic Physicians|Internal Medicine · YORKTOWN HEIGHTS, NY · NPI 1184738510
Verified facts
CMS Open Payments records show Daniela Spitzer, MD received $298.11 in general payments during 2025 across 2 reported records.
HEARTFLOW, INC. accounted for 52.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Payment overview · 2025
2 reported records · 2 companies
Separate record types
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $155.46 | 52.1% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$142.65 | 47.9% | 1 | 2025 |
What were the payments for?
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $298.11 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $155.46 | 1 | 2025 |
Source payment records
|
|||||
| O-ARM Normalized: o arm |
Device | Medtronic, Inc. | $142.65 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 543 | 179 |
| Amlodipine Besylate | Amlodipine Besylate | 298 | 104 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 290 | 102 |
| Losartan Potassium | Losartan Potassium | 272 | 92 |
| Levothyroxine Sodium | Levothyroxine Sodium | 261 | 90 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 191 | 79 |
| Metoprolol Succinate | Metoprolol Succinate | 191 | 64 |
| Simvastatin | Simvastatin | 181 | 59 |
| Metformin Hcl | Metformin Hcl | 173 | 63 |
| Omeprazole | Omeprazole | 161 | 64 |
| Hydrochlorothiazide | Hydrochlorothiazide | 135 | 49 |
| Meloxicam | Meloxicam | 132 | 38 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 127 | 32 |
| Lisinopril | Lisinopril | 123 | 42 |
| Alprazolam | Alprazolam | 119 | 28 |
| Azithromycin | Azithromycin | 118 | 96 |
| Zolpidem Tartrate | Zolpidem Tartrate | 117 | 21 |
| Valsartan | Valsartan | 110 | 28 |
| Ezetimibe | Ezetimibe | 104 | 34 |
| Montelukast Sodium | Montelukast Sodium | 100 | 37 |
| Pantoprazole Sodium | Pantoprazole Sodium | 95 | 30 |
| Furosemide | Furosemide | 87 | 34 |
| Gabapentin | Gabapentin | 86 | 35 |
| Famotidine | Famotidine | 83 | 27 |
| Trazodone Hcl | Trazodone Hcl | 83 | 33 |
| Prednisone | Prednisone | 82 | 60 |
| Escitalopram Oxalate | Escitalopram Oxalate | 74 | 27 |
| Metformin Hcl Er | Metformin Hcl | 74 | 22 |
| Jardiance | Empagliflozin | 70 | 26 |
| Sertraline Hcl | Sertraline Hcl | 70 | 23 |
| Allopurinol | Allopurinol | 69 | 22 |
| Atenolol | Atenolol | 65 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 61 | 34 |
| Carvedilol | Carvedilol | 58 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 58 | 18 |
| Potassium Chloride | Potassium Chloride | 57 | 21 |
| Doxycycline Hyclate | Doxycycline Hyclate | 55 | 45 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 53 | 43 |
| Azelastine Hcl | Azelastine Hcl | 53 | 20 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 52 | 42 |
| Synthroid | Levothyroxine Sodium | 52 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 49 | 16 |
| Tramadol Hcl | Tramadol Hcl | 48 | suppressed |
| Eliquis | Apixaban | 46 | 17 |
| Ketoconazole | Ketoconazole | 44 | 21 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 41 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 38 | 21 |
| Bupropion Xl | Bupropion Hcl | 37 | 12 |
| Nystatin | Nystatin | 37 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 37 | 15 |
| Nebivolol Hcl | Nebivolol Hcl | 35 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 34 | 12 |
| Glimepiride | Glimepiride | 34 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 34 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 34 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 32 | 29 |
| Buspirone Hcl | Buspirone Hcl | 31 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 31 | 12 |
| Irbesartan | Irbesartan | 31 | suppressed |
| Ramipril | Ramipril | 31 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | 14 |
| Telmisartan | Telmisartan | 27 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 26 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 26 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 26 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 25 | suppressed |
| Fluconazole | Fluconazole | 25 | 13 |
| Januvia | Sitagliptin Phosphate | 25 | suppressed |
| Ozempic | Semaglutide | 24 | suppressed |
| Spironolactone | Spironolactone | 24 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 23 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 22 | suppressed |
| Folic Acid | Folic Acid | 21 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Diazepam | Diazepam | 20 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Naproxen | Naproxen | 20 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 20 | suppressed |
| Vascepa | Icosapent Ethyl | 20 | suppressed |
| Clobetasol Emollient | Clobetasol Propionate/Emoll | 19 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Clonazepam | Clonazepam | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 18 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 16 |
| Temazepam | Temazepam | 16 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Prolia | Denosumab | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Cozaar | Losartan Potassium | 12 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Phenytoin | Phenytoin | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 11 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | 11 |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Livalo | Pitavastatin Calcium | 11 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $298.11 · 2 records | HEARTFLOW, INC. | FFRct, O-ARM | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error